1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effects of androgen deprivation therapy on prostate cancer outcomes according to competing event risk: Secondary analysis of a phase 3 randomised trial
    Journal Article

    Mell, L. K.; Pugh, S. L.; Jones, C. U.; Nelson, T. J.; Zakeri, K.; Rose, B. S.; Zeitzer, K. L.; Gore, E. M.; Bahary, J. P.; Souhami, L.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis
    Journal Article

    Piulats, J. M.; Watkins, C.; Costa-García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: An analysis of individual patient data from seven prospective trials
    Journal Article

    Guo, T.; Zhou, Y.; Liang, F.; Wang, Z.; Bourbonne, V.; Käsmann, L.; Sundahl, N.; Wu, A. J. C.; Ni, J.; Zhu, Z.
    Translational Lung Cancer Research (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
    Journal Article

    Powles, T.; Valderrama, B. P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Incidence, predictors, and impact of hospital readmission after revascularization for left main coronary disease
    Journal Article

    Kosmidou, I.; Shahim, B.; Dressler, O.; Redfors, B.; Morice, M. C.; Puskas, J. D.; Kandzari, D. E.; Karmpaliotis, D.; Brown, W. M. 3rd; Lembo, N. J.; more...
    Journal of the American College of Cardiology (2024)

    Fulltext@MSK | Save
  • Analysis of East Asia subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
    Journal Article

    Yonemori, K.; Fujiwara, K.; Hasegawa, K.; Yunokawa, M.; Ushijima, K.; Suzuki, S.; Shikama, A.; Minobe, S.; Usami, T.; Kim, J. W.; more...
    Journal of Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Treatment for first cytomegalovirus infection post–hematopoietic cell transplant in the AURORA trial: A multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir
    Journal Article

    Papanicolaou, G. A.; Avery, R. K.; Cordonnier, C.; Duarte, R. F.; Haider, S.; Maertens, J.; Peggs, K. S.; Solano, C.; Young, J. A. H.; Fournier, M.; more...
    Clinical Infectious Diseases (2024)

    Fulltext@MSK | Save
  • Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
    Journal Article

    Seiwert, T. Y.; Wildsmith, S.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M. J.; Takahashi, S.; Weiss, J.; Machiels, J. P.; Baxi, S.; more...
    Cancer Immunology, Immunotherapy (2024)

    Fulltext@MSK | Save
  • A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer
    Journal Article

    Rodón, J.; Demanse, D.; Rugo, H. S.; Burris, H. A.; Simó, R.; Farooki, A.; Wellons, M. F.; André, F.; Hu, H.; Vuina, D.; more...
    Breast Cancer Research (2024)

    Fulltext@MSK | Save